Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

MyeloMATCH MSRP: En screeningstudie for å tildele personer med myeloide kreft til en behandlingsstudie

30. oktober 2026 oppdatert av: National Cancer Institute (NCI)

Master Screening and Reassessment Protocol (MSRP) for NCI MyeloMATCH Clinical Trials

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

Studieoversikt

Detaljert beskrivelse

PRIMARY OBJECTIVES:

I. Screening and Reassessment (MSRP): To evaluate the feasibility of MATCHBox receiving and organizing all data needed for assignment to a myeloMATCH clinical trial or Tier Advancement Pathway (TAP) within 72 hours of MDNet receipt of all required specimens for initial therapy and within 10 days for subsequent therapy.

II. Tier Advancement Pathway (TAP): To enable participants who are not matched to an investigational myeloMATCH treatment substudy to receive standard of care (SOC) while remaining on the MSRP to maintain access to later tiers of treatment substudies.

SECONDARY OBJECTIVES:

I. Screening and Reassessment (MSRP):

Ia. To describe the time to generation of all data required for treatment substudy (or TAP) assignment, time to treatment substudy (or TAP) assignment, percent assigned to a myeloMATCH treatment substudy, and the percent of screened participants who register to a myeloMATCH investigational treatment substudy or are assigned to TAP:

Iai. Separately within each tier of myeloMATCH treatment substudy and analogous TAP assignment; Ibi. Separately within each clinical basket of myeloMATCH treatment substudies; Ici. Over time, across and within the categories above.

II. Tier Advancement Pathway (TAP):

IIa. To evaluate participants for assignment to higher tier treatment substudies within myeloMATCH; IIb. To describe, within tier- and basket- levels of TAP, measurable residual disease (MRD) rates and clonal evolution; IIc. To describe, within tier- and basket- levels of TAP, remission status and overall survival of participants who receive standard of care therapy; IId. To obtain MDNet specimens for translational medicine and biobanking.

OUTLINE:

REGISTRATION: Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a specific substudy containing a therapy targeted to the patient's mutational profile. If there is no targetable mutation, the patient is placed on a substudy testing novel combinations that do not contain a target-specific drug. Patients who are not eligible for any MYELOMATCH substudy are assigned to TAP.

TAP: Patients continue SOC treatment and undergo continued bone marrow aspiration and blood collection for possible future substudy assignment.

TREATMENT: Patients are assigned to a specific treatment substudy.

MM1YA-CTG01: Younger patients (age 18-59 years) with intermediate risk acute myeloid leukemia (AML) are randomized to 1 of 3 arms.

ARM I: Patients receive daunorubicin intravenously (IV) on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax orally (PO) once daily (QD) on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening.

ARM II: Patients receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

ARM III: Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

MM1YA-S01: Younger patients (age 18-59 years) with high-risk AML are randomized to 1 of 5 arms.

ARM I: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

ARM II: Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

ARM III: Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

ARM IV: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

ARM V: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

MM2YA-EA01: Younger patients (age 18-59 years) with AML or secondary AML who have completed a tier 1 MyeloMATCH treatment study with complete remission (CR) or CR with partial hematologic recovery (CRh) and have detectable minimal residual disease (MRD) (> 0.1%) are randomized to 1 of 4 arms.

ARM A: Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.

ARM B: Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.

ARM C: Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.

ARM D: Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.

MM1OA-EA02: Patients are randomized to 1 of 3 regimens.

REGIMEN 1:

INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

REGIMEN 2:

INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

REGIMEN 3:

INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

MM1MDS-A01: Patients are randomized to 1 of 2 regimens.

REGIMEN 1: Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 1. Patients who experience CR, PR, or stable disease (SD) any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.

REGIMEN 2: Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.

MM1OA-S03: Patients are randomized to 1 of 2 arms.

ARM 1: Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.

ARM 2: Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.

MM1YA-A04: Patients are randomized to 1 of 2 regimens.

REGIMEN 1: Patients receive gemtuzumab ozogamicin IV on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study.

REGIMEN 2: Patients receive venetoclax PO QD on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study.

MM3TCT-A03: Patients with matched donors are randomized to conditioning 1A or 1B. Patients with haploidentical or mismatched unrelated donors are randomized to conditioning 2A or 2B.

CONDITIONING 1A: Patients receive venetoclax PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or twice daily (BID) on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.

CONDITIONING 1B: Patients receive placebo PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.

CONDITIONING 2A: Patients receive venetoclax PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.

CONDITIONING 2B: Patients receive placebo PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: All patients without evidence of relapse at day +100 are re-randomized to maintenance I or II.

MAINTENANCE I: Patients receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity.

MAINTENANCE II: Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity.

Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo positron emission tomography (PET) scan and/or computed tomography (CT) scan throughout the study.

MM1OA-MDS-A05: Patients are assigned to 1 of 3 cohorts.

COHORT A: Patients are randomized to 1 of 2 arms.

ARM 1: Patients receive ASTX727 PO QD on days 1-5 of each cycle and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

ARM 2: Patients receive ASTX727 PO QD on days 1-5 of each cycle, venetoclax PO QD on days 1-28 of each cycle, and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

COHORT B: Patients are randomized to 1 of 2 arms.

ARM 3: Patients receive ASTX727 PO QD on days 1-5 of each cycle and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

ARM 4: Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients without CR after cycle 6 may then cross-over to Arm 3. Patients with CR, as well as patients without CR but deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

COHORT C: Patients receive olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

MM1MDS-CTG02: This is a dose-escalation study of luspatercept in combination, dependent upon arms assignments, with fixed dose epoetin alfa or emavusertib. Patients are randomized to 1 of 3 arms.

ARM 1: Patients receive luspatercept SC on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

ARM 2: Patients receive luspatercept SC on day 1 and epoetin alfa SC once weekly (QW) for each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

ARM 3: Patients receive luspatercept SC on day 1 and emavusertib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

MM1YA-EA05: Patients are randomized to 1 of 2 arms.

ARM A:

INDUCTION: Patients receive cytarabine IV, over 24 hours, on days 1-7, daunorubicin IV on days 1-3, and quizartinib PO QD on days 8-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspiration/biopsy. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts may repeat induction as described starting on day 28-45. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts proceed to consolidation, following count recovery, by 30 days post-confirmation of CR/CRi. Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts repeat the bone marrow aspiration/biopsy 1 week later and then either repeat induction or proceed to consolidation, based on results. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts proceed to consolidation.

CONSOLIDATION: Patients receive cytarabine IV, over 1-3 hours, every 12 hours on days 1, 3 and 5 and quizartinib PO QD on days 6-19 in the absence of disease progression or unacceptable toxicity.

ARM B:

CYCLE 1: Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9, venetoclax PO QD on days 1-28, and quizartinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity and based on bone marrow findings. Patients undergo bone marrow aspiration/biopsy on day 14 of cycle 1. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts continue treatment as described through day 28 of cycle 1 and then proceed to cycle 2 without interruption or delay, as long as repeat bone marrow aspiration/biopsy on day 28 of cycle 1 is consistent with persistent blasts > 5%. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28) and then proceed to cycle 2 of treatment as described following count recovery. Patients without count recovery by day 42 undergo repeat bone marrow aspiration/biopsy. Patients with count recovery by day 42 proceed to cycle 2 (by day 50). For patients without count recovery by day 50 whose repeat bone marrow aspiration/biopsy shows no blasts, initiation of cycle 2 will be discussed with the study chairs. Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib, undergo repeat bone marrow aspiration/biopsy 1 week later, and proceed based on repeat biopsy results as described. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28) and then proceed to cycle 2 of treatment as described following count recovery. Patients without count recovery by day 42 undergo repeat bone marrow aspiration/biopsy. Patients with count recovery by day 42 proceed to cycle 2 (by day 50). For patients without count recovery by day 50 whose repeat bone marrow aspiration/biopsy shows no blasts, initiation of cycle 2 will be discussed with the study chairs.

CYCLE 2: Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9, venetoclax PO QD on days 1-28, and quizartinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity and based on bone marrow findings. Patients who do not achieve response after completion of cycle 1 undergo bone marrow aspiration/biopsy on day 14 of cycle 2. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts continue venetoclax and quizartinib as described through day 28 of cycle 2. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28). Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib, undergo repeat bone marrow aspiration/biopsy 1 week later, and proceed based on repeat aspiration/biopsy results as described. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28).

Upon completion of two cycles of therapy on either Arm A or Arm B, patients who are eligible can proceed to allogeneic stem cell transplant; while awaiting allogeneic stem cell transplant, patients should continue standard of care therapy.

Patients undergo echocardiography or MUGA scan during screening and undergo bone marrow aspiration and biopsy as well as blood sample collection throughout the study.

Studietype

Intervensjonell

Registrering (Antatt)

2000

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Rekruttering
        • Arthur J E Child Comprehensive Cancer Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mary L. Savoie
      • Edmonton, Alberta, Canada, T6G 2B7
        • Rekruttering
        • University of Alberta Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Joseph M. Brandwein
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Rekruttering
        • CancerCare Manitoba
        • Ta kontakt med:
        • Hovedetterforsker:
          • Brett L. Houston
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • Rekruttering
        • QEII Health Sciences Centre/Nova Scotia Health Authority
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 902-473-6000
        • Hovedetterforsker:
          • Mahmoud Elsawy
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Rekruttering
        • Juravinski Cancer Centre at Hamilton Health Sciences
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 905-387-9495
        • Hovedetterforsker:
          • Alejandro Garcia-Horton
      • Ottawa, Ontario, Canada, K1H 8L6
        • Rekruttering
        • Ottawa Hospital and Cancer Center-General Campus
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 613-761-4395
        • Hovedetterforsker:
          • Mitchell Sabloff
      • Toronto, Ontario, Canada, M5G 2M9
        • Suspendert
        • University Health Network-Princess Margaret Hospital
      • Toronto, Ontario, Canada, M4N 3M5
        • Rekruttering
        • Odette Cancer Centre- Sunnybrook Health Sciences Centre
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 416-480-5000
        • Hovedetterforsker:
          • Rena J. Buckstein
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • Rekruttering
        • CSSS Champlain-Charles Le Moyne
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 450-466-5065
        • Hovedetterforsker:
          • Sami Morin-Ben Abdallah
      • Montreal, Quebec, Canada, H3T 1E2
        • Rekruttering
        • Jewish General Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 8248 514-340-8222
        • Hovedetterforsker:
          • Sarit E. Assouline
      • Montreal, Quebec, Canada, H1T 2M4
        • Rekruttering
        • CIUSSSEMTL-Hopital Maisonneuve-Rosemont
        • Hovedetterforsker:
          • Julie Bergeron
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 3329 514-252-3400
    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • Rekruttering
        • University of Alabama at Birmingham Cancer Center
        • Hovedetterforsker:
          • Razan Mohty
        • Ta kontakt med:
    • Arizona
      • Phoenix, Arizona, Forente stater, 85054
        • Rekruttering
        • Mayo Clinic Hospital in Arizona
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 855-776-0015
        • Hovedetterforsker:
          • James M. Foran
      • Tucson, Arizona, Forente stater, 85719
        • Rekruttering
        • Banner University Medical Center - Tucson
        • Hovedetterforsker:
          • Sharad Khurana
        • Ta kontakt med:
      • Tucson, Arizona, Forente stater, 85719
        • Rekruttering
        • University of Arizona Cancer Center-North Campus
        • Hovedetterforsker:
          • Sharad Khurana
        • Ta kontakt med:
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72205
        • Rekruttering
        • University of Arkansas for Medical Sciences
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 501-686-8274
        • Hovedetterforsker:
          • Ankur Varma
    • California
      • Berkeley, California, Forente stater, 94704
        • Aktiv, ikke rekrutterende
        • Alta Bates Summit Medical Center-Herrick Campus
      • Dublin, California, Forente stater, 94568
        • Rekruttering
        • Kaiser Permanente Dublin
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
        • Hovedetterforsker:
          • Faisal N. Cheema
      • Fremont, California, Forente stater, 94538
        • Rekruttering
        • Kaiser Permanente-Fremont
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • Fresno, California, Forente stater, 93720
        • Suspendert
        • Kaiser Permanente-Fresno
      • Fresno, California, Forente stater, 93720
        • Rekruttering
        • Kaiser Permanente Fresno Orchard Plaza
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 833-574-2273
        • Hovedetterforsker:
          • Faisal N. Cheema
      • Irvine, California, Forente stater, 92612
        • Rekruttering
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
        • Hovedetterforsker:
          • Deepa Jeyakumar
        • Ta kontakt med:
      • Long Beach, California, Forente stater, 90822
        • Aktiv, ikke rekrutterende
        • Tibor Rubin VA Medical Center
      • Los Angeles, California, Forente stater, 90048
        • Rekruttering
        • Cedars-Sinai Medical Center
        • Hovedetterforsker:
          • Noah M. Merin
        • Ta kontakt med:
      • Modesto, California, Forente stater, 95356
        • Suspendert
        • Kaiser Permanente-Modesto
      • Modesto, California, Forente stater, 95356
        • Rekruttering
        • Kaiser Permanente- Modesto MOB II
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
        • Hovedetterforsker:
          • Faisal N. Cheema
      • Oakland, California, Forente stater, 94611
        • Rekruttering
        • Kaiser Permanente-Oakland
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • Orange, California, Forente stater, 92868
        • Rekruttering
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
        • Hovedetterforsker:
          • Deepa Jeyakumar
        • Ta kontakt med:
      • Roseville, California, Forente stater, 95661
        • Rekruttering
        • Kaiser Permanente-Roseville
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • Sacramento, California, Forente stater, 95817
        • Rekruttering
        • University of California Davis Comprehensive Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 916-734-3089
        • Hovedetterforsker:
          • Brian A. Jonas
      • Sacramento, California, Forente stater, 95814
        • Rekruttering
        • Kaiser Permanente Downtown Commons
        • Hovedetterforsker:
          • Faisal N. Cheema
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: kpoct@kp.org
      • Sacramento, California, Forente stater, 95823
        • Rekruttering
        • Kaiser Permanente-South Sacramento
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • San Francisco, California, Forente stater, 94115
        • Rekruttering
        • Kaiser Permanente-San Francisco
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • San Francisco, California, Forente stater, 94143
        • Rekruttering
        • UCSF Medical Center-Parnassus
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-827-3222
        • Hovedetterforsker:
          • Timothy Ferng
      • San Jose, California, Forente stater, 95119
        • Rekruttering
        • Kaiser Permanente-Santa Teresa-San Jose
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • San Leandro, California, Forente stater, 94577
        • Rekruttering
        • Kaiser Permanente San Leandro
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • San Rafael, California, Forente stater, 94903
        • Rekruttering
        • Kaiser San Rafael-Gallinas
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • Santa Clara, California, Forente stater, 95051
        • Rekruttering
        • Kaiser Permanente Medical Center - Santa Clara
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • Santa Rosa, California, Forente stater, 95403
        • Rekruttering
        • Kaiser Permanente-Santa Rosa
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • South San Francisco, California, Forente stater, 94080
        • Rekruttering
        • Kaiser Permanente-South San Francisco
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • Vallejo, California, Forente stater, 94589
        • Rekruttering
        • Kaiser Permanente-Vallejo
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
      • Walnut Creek, California, Forente stater, 94596
        • Rekruttering
        • Kaiser Permanente-Walnut Creek
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-post: Kpoct@kp.org
        • Hovedetterforsker:
          • Faisal N. Cheema
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06520
        • Rekruttering
        • Yale University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jan P. Bewersdorf
      • West Haven, Connecticut, Forente stater, 06516
        • Rekruttering
        • Veterans Affairs Connecticut Healthcare System-West Haven Campus
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 2832 203-937-3421
        • Hovedetterforsker:
          • Alexander Pine
    • Florida
      • Gainesville, Florida, Forente stater, 32610
        • Rekruttering
        • UF Health Cancer Institute - Gainesville
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 352-273-8010
        • Hovedetterforsker:
          • Dina G. Khalaf
      • Jacksonville, Florida, Forente stater, 32224-9980
        • Rekruttering
        • Mayo Clinic in Florida
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 855-776-0015
        • Hovedetterforsker:
          • James M. Foran
      • Miami, Florida, Forente stater, 33176
        • Rekruttering
        • Miami Cancer Institute
        • Hovedetterforsker:
          • Firas El Chaer
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 786-596-2000
      • Pembroke Pines, Florida, Forente stater, 33028
        • Rekruttering
        • Memorial Hospital West
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 954-265-4325
        • Hovedetterforsker:
          • Yehuda E. Deutsch
      • Ruskin, Florida, Forente stater, 33570
        • Rekruttering
        • Moffitt Cancer Center at SouthShore
        • Hovedetterforsker:
          • Rory M. Shallis
        • Ta kontakt med:
      • Tampa, Florida, Forente stater, 33607
        • Rekruttering
        • Moffitt Cancer Center-International Plaza
        • Hovedetterforsker:
          • Rory M. Shallis
        • Ta kontakt med:
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • Moffitt Cancer Center - McKinley Campus
        • Hovedetterforsker:
          • Rory M. Shallis
        • Ta kontakt med:
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • Moffitt Cancer Center
        • Hovedetterforsker:
          • Rory M. Shallis
        • Ta kontakt med:
      • Wesley Chapel, Florida, Forente stater, 33544
        • Rekruttering
        • Moffitt Cancer Center at Wesley Chapel
        • Hovedetterforsker:
          • Rory M. Shallis
        • Ta kontakt med:
    • Georgia
      • Albany, Georgia, Forente stater, 31701
        • Rekruttering
        • Phoebe Putney Memorial Hospital
        • Hovedetterforsker:
          • Vamsi Kota
        • Ta kontakt med:
      • Augusta, Georgia, Forente stater, 30912
        • Rekruttering
        • Augusta University Medical Center
        • Hovedetterforsker:
          • Vamsi Kota
        • Ta kontakt med:
    • Hawaii
      • Honolulu, Hawaii, Forente stater, 96826
        • Rekruttering
        • Kapiolani Medical Center for Women and Children
        • Hovedetterforsker:
          • Craig S. Boddy
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 808-983-6090
      • Honolulu, Hawaii, Forente stater, 96813
        • Rekruttering
        • Hawaii Cancer Care Inc - Waterfront Plaza
        • Hovedetterforsker:
          • Craig S. Boddy
        • Ta kontakt med:
      • Honolulu, Hawaii, Forente stater, 96813
        • Rekruttering
        • Straub Clinic and Hospital
        • Hovedetterforsker:
          • Craig S. Boddy
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 808-522-4333
      • Honolulu, Hawaii, Forente stater, 96819
        • Rekruttering
        • Kaiser Permanente Moanalua Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Faisal N. Cheema
      • ‘Aiea, Hawaii, Forente stater, 96701
        • Rekruttering
        • Hawaii Cancer Care - Westridge
        • Hovedetterforsker:
          • Craig S. Boddy
        • Ta kontakt med:
      • ‘Aiea, Hawaii, Forente stater, 96701
        • Rekruttering
        • Pali Momi Medical Center
        • Hovedetterforsker:
          • Craig S. Boddy
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 808-486-6000
    • Idaho
      • Boise, Idaho, Forente stater, 83712
        • Rekruttering
        • Saint Luke's Cancer Institute - Boise
        • Ta kontakt med:
        • Hovedetterforsker:
          • Charles W. Drescher
      • Boise, Idaho, Forente stater, 83706
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Boise
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Caldwell, Idaho, Forente stater, 83605
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Caldwell
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Coeur d'Alene, Idaho, Forente stater, 83814
        • Rekruttering
        • Kootenai Health - Coeur d'Alene
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Fruitland, Idaho, Forente stater, 83619
        • Rekruttering
        • Saint Luke's Cancer Institute - Fruitland
        • Ta kontakt med:
        • Hovedetterforsker:
          • Charles W. Drescher
      • Meridian, Idaho, Forente stater, 83642
        • Rekruttering
        • Saint Luke's Cancer Institute - Meridian
        • Ta kontakt med:
        • Hovedetterforsker:
          • Charles W. Drescher
      • Nampa, Idaho, Forente stater, 83687
        • Rekruttering
        • Saint Luke's Cancer Institute - Nampa
        • Ta kontakt med:
        • Hovedetterforsker:
          • Charles W. Drescher
      • Nampa, Idaho, Forente stater, 83687
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Nampa
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Post Falls, Idaho, Forente stater, 83854
        • Rekruttering
        • Kootenai Clinic Cancer Services - Post Falls
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Sandpoint, Idaho, Forente stater, 83864
        • Rekruttering
        • Kootenai Clinic Cancer Services - Sandpoint
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
    • Illinois
      • Aurora, Illinois, Forente stater, 60506
        • Rekruttering
        • Advocate Outpatient Center - Aurora
        • Hovedetterforsker:
          • Thomas J. Saphner
        • Ta kontakt med:
      • Barrington, Illinois, Forente stater, 60010
        • Rekruttering
        • Advocate Good Shepherd Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 847-842-4847
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Bloomington, Illinois, Forente stater, 61704
        • Rekruttering
        • Illinois CancerCare-Bloomington
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Bloomington, Illinois, Forente stater, 61701
        • Rekruttering
        • OSF Saint Joseph Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Canton, Illinois, Forente stater, 61520
        • Rekruttering
        • Illinois CancerCare-Canton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Carthage, Illinois, Forente stater, 62321
        • Rekruttering
        • Illinois CancerCare-Carthage
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • University of Chicago Comprehensive Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Olatoyosi M. Odenike
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Northwestern University
        • Hovedetterforsker:
          • Jessica K. Altman
        • Ta kontakt med:
      • Chicago, Illinois, Forente stater, 60612
        • Rekruttering
        • University of Illinois
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 312-355-3046
        • Hovedetterforsker:
          • Noah Birch
      • Chicago, Illinois, Forente stater, 60657
        • Rekruttering
        • Advocate Illinois Masonic Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 773-296-5360
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Chicago, Illinois, Forente stater, 60612
        • Rekruttering
        • Rush MD Anderson Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Melissa L. Larson
      • Crystal Lake, Illinois, Forente stater, 60014
        • Rekruttering
        • AMG Crystal Lake - Oncology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Danville, Illinois, Forente stater, 61832
        • Rekruttering
        • Carle at The Riverfront
        • Hovedetterforsker:
          • Suparna Mantha
        • Ta kontakt med:
      • DeKalb, Illinois, Forente stater, 60115
        • Rekruttering
        • Northwestern Medicine Cancer Center Kishwaukee
        • Hovedetterforsker:
          • Jessica K. Altman
        • Ta kontakt med:
      • Decatur, Illinois, Forente stater, 62526
        • Rekruttering
        • Cancer Care Specialists of Illinois - Decatur
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
      • Decatur, Illinois, Forente stater, 62526
        • Rekruttering
        • Decatur Memorial Hospital
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
      • Dixon, Illinois, Forente stater, 61021
        • Rekruttering
        • Illinois CancerCare-Dixon
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 815-285-7800
      • Downers Grove, Illinois, Forente stater, 60515
        • Rekruttering
        • Advocate Good Samaritan Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Effingham, Illinois, Forente stater, 62401
        • Rekruttering
        • Carle Physician Group-Effingham
        • Hovedetterforsker:
          • Suparna Mantha
        • Ta kontakt med:
      • Effingham, Illinois, Forente stater, 62401
        • Rekruttering
        • Crossroads Cancer Center
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
      • Elgin, Illinois, Forente stater, 60123
        • Rekruttering
        • Advocate Sherman Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 847-429-2907
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Eureka, Illinois, Forente stater, 61530
        • Rekruttering
        • Illinois CancerCare-Eureka
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Evanston, Illinois, Forente stater, 60201
        • Rekruttering
        • NorthShore University HealthSystem-Evanston Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 847-570-2109
        • Hovedetterforsker:
          • Robert M. Eisner
      • Galesburg, Illinois, Forente stater, 61401
        • Rekruttering
        • Illinois CancerCare-Galesburg
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Geneva, Illinois, Forente stater, 60134
        • Rekruttering
        • Northwestern Medicine Cancer Center Delnor
        • Hovedetterforsker:
          • Jessica K. Altman
        • Ta kontakt med:
      • Glenview, Illinois, Forente stater, 60026
        • Rekruttering
        • NorthShore University HealthSystem-Glenbrook Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 847-570-2109
        • Hovedetterforsker:
          • Robert M. Eisner
      • Glenview, Illinois, Forente stater, 60026
        • Rekruttering
        • Northwestern Medicine Glenview Outpatient Center
        • Hovedetterforsker:
          • Jessica K. Altman
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 312-695-1102
      • Grayslake, Illinois, Forente stater, 60030
        • Rekruttering
        • Northwestern Medicine Grayslake Outpatient Center
        • Hovedetterforsker:
          • Jessica K. Altman
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 312-695-1102
      • Harvey, Illinois, Forente stater, 60426
        • Rekruttering
        • Ingalls Memorial Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kimberly R. Kruczek
      • Hazel Crest, Illinois, Forente stater, 60429
        • Rekruttering
        • Advocate South Suburban Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 708-799-9995
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Highland Park, Illinois, Forente stater, 60035
        • Rekruttering
        • NorthShore University HealthSystem-Highland Park Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 847-570-2109
        • Hovedetterforsker:
          • Robert M. Eisner
      • Hines, Illinois, Forente stater, 60141
        • Rekruttering
        • Edward Hines Jr VA Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 708-202-8387
        • Hovedetterforsker:
          • Jorgena Kosti-Schwartz
      • Kewanee, Illinois, Forente stater, 61443
        • Rekruttering
        • Illinois CancerCare-Kewanee Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Lake Forest, Illinois, Forente stater, 60045
        • Rekruttering
        • Northwestern Medicine Lake Forest Hospital
        • Hovedetterforsker:
          • Jessica K. Altman
        • Ta kontakt med:
      • Libertyville, Illinois, Forente stater, 60048
        • Rekruttering
        • AMG Libertyville - Oncology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Libertyville, Illinois, Forente stater, 60048
        • Rekruttering
        • Condell Memorial Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Macomb, Illinois, Forente stater, 61455
        • Rekruttering
        • Illinois CancerCare-Macomb
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Mattoon, Illinois, Forente stater, 61938
        • Rekruttering
        • Carle Physician Group-Mattoon/Charleston
        • Hovedetterforsker:
          • Suparna Mantha
        • Ta kontakt med:
      • Maywood, Illinois, Forente stater, 60153
        • Rekruttering
        • Loyola University Medical Center
        • Hovedetterforsker:
          • Stephanie B. Tsai
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 708-226-4357
      • O'Fallon, Illinois, Forente stater, 62269
        • Rekruttering
        • Cancer Care Center of O'Fallon
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
      • Oak Lawn, Illinois, Forente stater, 60453-2699
        • Rekruttering
        • Advocate Christ Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-323-8622
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Oak Lawn, Illinois, Forente stater, 60453
        • Rekruttering
        • Advocate Outpatient Center - Oak Lawn
        • Hovedetterforsker:
          • Thomas J. Saphner
        • Ta kontakt med:
      • Orland Park, Illinois, Forente stater, 60462
      • Ottawa, Illinois, Forente stater, 61350
        • Rekruttering
        • Illinois CancerCare-Ottawa Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Palos Heights, Illinois, Forente stater, 60463
        • Rekruttering
        • Advocate High Tech Medical Park
        • Hovedetterforsker:
          • Thomas J. Saphner
        • Ta kontakt med:
      • Park Ridge, Illinois, Forente stater, 60068
        • Rekruttering
        • Advocate Lutheran General Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 847-384-3621
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Pekin, Illinois, Forente stater, 61554
        • Rekruttering
        • Illinois CancerCare-Pekin
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Peoria, Illinois, Forente stater, 61615
        • Rekruttering
        • Illinois CancerCare-Peoria
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Peoria, Illinois, Forente stater, 61636
        • Rekruttering
        • Methodist Medical Center of Illinois
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Peoria, Illinois, Forente stater, 61637
        • Rekruttering
        • OSF Saint Francis Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Peru, Illinois, Forente stater, 61354
        • Rekruttering
        • Illinois CancerCare-Peru
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Princeton, Illinois, Forente stater, 61356
        • Rekruttering
        • Illinois CancerCare-Princeton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
      • Springfield, Illinois, Forente stater, 62702
        • Rekruttering
        • Southern Illinois University School of Medicine
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 217-545-7929
      • Springfield, Illinois, Forente stater, 62702
        • Rekruttering
        • Springfield Clinic
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-444-7541
      • Springfield, Illinois, Forente stater, 62781
        • Rekruttering
        • Springfield Memorial Hospital
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
      • Urbana, Illinois, Forente stater, 61801
        • Rekruttering
        • Carle Cancer Center
        • Hovedetterforsker:
          • Suparna Mantha
        • Ta kontakt med:
      • Warrenville, Illinois, Forente stater, 60555
        • Rekruttering
        • Northwestern Medicine Cancer Center Warrenville
        • Hovedetterforsker:
          • Jessica K. Altman
        • Ta kontakt med:
      • Washington, Illinois, Forente stater, 61571
        • Rekruttering
        • Illinois CancerCare - Washington
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bryan A. Faller
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Rekruttering
        • Indiana University/Melvin and Bren Simon Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Rita Assi
    • Iowa
      • Ankeny, Iowa, Forente stater, 50023
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hovedetterforsker:
          • Seema Harichand-Herdt
      • Clive, Iowa, Forente stater, 50325
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hovedetterforsker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Forente stater, 50314
        • Rekruttering
        • Mercy Medical Center - Des Moines
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hovedetterforsker:
          • Richard L. Deming
      • Des Moines, Iowa, Forente stater, 50309
        • Rekruttering
        • Iowa Methodist Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 515-241-6727
        • Hovedetterforsker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Forente stater, 50309
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hovedetterforsker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Forente stater, 50314
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hovedetterforsker:
          • Seema Harichand-Herdt
      • Iowa City, Iowa, Forente stater, 52242
        • Rekruttering
        • University of Iowa/Holden Comprehensive Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-237-1225
        • Hovedetterforsker:
          • Prajwal Dhakal
      • Pella, Iowa, Forente stater, 50219
        • Rekruttering
        • UI Healthcare Mission Cancer and Blood - Pella
        • Hovedetterforsker:
          • Seema Harichand-Herdt
        • Ta kontakt med:
      • Waukee, Iowa, Forente stater, 50263
        • Rekruttering
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hovedetterforsker:
          • Seema Harichand-Herdt
      • West Des Moines, Iowa, Forente stater, 50266
        • Rekruttering
        • The Iowa Clinic PC
        • Hovedetterforsker:
          • Seema Harichand-Herdt
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 515-875-9815
    • Kansas
      • Fairway, Kansas, Forente stater, 66205
        • Rekruttering
        • University of Kansas Clinical Research Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tara L. Lin
      • Hays, Kansas, Forente stater, 67601
        • Rekruttering
        • HaysMed
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 785-623-5774
        • Hovedetterforsker:
          • Tara L. Lin
      • Kansas City, Kansas, Forente stater, 66160
        • Rekruttering
        • University of Kansas Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tara L. Lin
      • Lawrence, Kansas, Forente stater, 66044
        • Rekruttering
        • Lawrence Memorial Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tara L. Lin
      • Olathe, Kansas, Forente stater, 66061
        • Rekruttering
        • The University of Kansas Cancer Center - Olathe
        • Hovedetterforsker:
          • Tara L. Lin
        • Ta kontakt med:
      • Overland Park, Kansas, Forente stater, 66211
        • Rekruttering
        • University of Kansas Hospital-Indian Creek Campus
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tara L. Lin
      • Overland Park, Kansas, Forente stater, 66210
        • Rekruttering
        • University of Kansas Cancer Center-Overland Park
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tara L. Lin
      • Salina, Kansas, Forente stater, 67401
        • Rekruttering
        • Salina Regional Health Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tara L. Lin
      • Topeka, Kansas, Forente stater, 66606
        • Rekruttering
        • University of Kansas Health System Saint Francis Campus
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 785-295-8000
        • Hovedetterforsker:
          • Tara L. Lin
      • Topeka, Kansas, Forente stater, 66606
        • Suspendert
        • Cotton O'Neil Cancer Center / Stormont Vail Health
      • Westwood, Kansas, Forente stater, 66205
        • Rekruttering
        • University of Kansas Hospital-Westwood Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tara L. Lin
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40536
        • Rekruttering
        • University of Kentucky/Markey Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 859-257-3379
        • Hovedetterforsker:
          • Ayman Qasrawi
      • Louisville, Kentucky, Forente stater, 40202
        • Rekruttering
        • The James Graham Brown Cancer Center at University of Louisville
        • Hovedetterforsker:
          • Mohamed M. Hegazi
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 502-562-3429
      • Louisville, Kentucky, Forente stater, 40245
        • Rekruttering
        • UofL Health Medical Center Northeast
        • Hovedetterforsker:
          • Mohamed M. Hegazi
        • Ta kontakt med:
    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70805
        • Rekruttering
        • LSU Health Baton Rouge-North Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Harry G. Sequeira Gross
      • Baton Rouge, Louisiana, Forente stater, 70808
        • Rekruttering
        • Our Lady of The Lake
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 225-765-7659
        • Hovedetterforsker:
          • Harry G. Sequeira Gross
      • Baton Rouge, Louisiana, Forente stater, 70808
        • Rekruttering
        • Our Lady of the Lake Physician Group
        • Ta kontakt med:
        • Hovedetterforsker:
          • Harry G. Sequeira Gross
    • Maine
      • Brunswick, Maine, Forente stater, 04011
        • Rekruttering
        • Mid Coast Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pamela Egan
      • Brunswick, Maine, Forente stater, 04011
        • Rekruttering
        • MaineHealth Cancer Care and IV Therapy - Brunswick
        • Hovedetterforsker:
          • Pamela Egan
        • Ta kontakt med:
      • Portland, Maine, Forente stater, 04102
        • Rekruttering
        • MaineHealth Maine Medical Center - Portland
        • Hovedetterforsker:
          • Pamela Egan
        • Ta kontakt med:
      • Scarborough, Maine, Forente stater, 04074
        • Rekruttering
        • MaineHealth Maine Medical Center- Scarborough
        • Hovedetterforsker:
          • Pamela Egan
        • Ta kontakt med:
      • South Portland, Maine, Forente stater, 04106
        • Rekruttering
        • MaineHealth Cancer Care and IV Therapy - South Portland
        • Hovedetterforsker:
          • Pamela Egan
        • Ta kontakt med:
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • Rekruttering
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander J. Ambinder
      • Bethesda, Maryland, Forente stater, 20889-5600
        • Suspendert
        • Walter Reed National Military Medical Center
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Dana-Farber Cancer Institute
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-442-3324
        • Hovedetterforsker:
          • Richard M. Stone
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Beth Israel Deaconess Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 617-667-9925
        • Hovedetterforsker:
          • Malgorzata McMasters
      • Boston, Massachusetts, Forente stater, 02111
      • Worcester, Massachusetts, Forente stater, 01655
        • Rekruttering
        • UMass Memorial Medical Center - University Campus
        • Hovedetterforsker:
          • Jan Cerny
        • Ta kontakt med:
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48106
        • Rekruttering
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Brighton, Michigan, Forente stater, 48114
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Canton, Michigan, Forente stater, 48188
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Chelsea, Michigan, Forente stater, 48118
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Clinton Township, Michigan, Forente stater, 48038
        • Rekruttering
        • Henry Ford Macomb Hospital-Clinton Township
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ahmad H. Mattour
      • Detroit, Michigan, Forente stater, 48201
        • Rekruttering
        • Wayne State University/Karmanos Cancer Institute
        • Hovedetterforsker:
          • Vijendra Singh
        • Ta kontakt med:
      • Detroit, Michigan, Forente stater, 48202
        • Rekruttering
        • Henry Ford Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ahmad H. Mattour
      • Farmington Hills, Michigan, Forente stater, 48334
        • Rekruttering
        • Weisberg Cancer Treatment Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Vijendra Singh
      • Flint, Michigan, Forente stater, 48503
        • Rekruttering
        • Genesys Hurley Cancer Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Flint, Michigan, Forente stater, 48503
        • Rekruttering
        • Hurley Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Flint, Michigan, Forente stater, 48503
        • Suspendert
        • Genesee Hematology Oncology PC
      • Flint, Michigan, Forente stater, 48503
        • Rekruttering
        • Cancer Hematology Centers - Flint
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Jackson, Michigan, Forente stater, 49201
        • Rekruttering
        • Allegiance Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ahmad H. Mattour
      • Livonia, Michigan, Forente stater, 48154
        • Rekruttering
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Novi, Michigan, Forente stater, 48377
        • Rekruttering
        • Henry Ford Medical Center-Columbus
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ahmad H. Mattour
      • Pontiac, Michigan, Forente stater, 48341
        • Rekruttering
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • West Bloomfield, Michigan, Forente stater, 48322
        • Rekruttering
        • Henry Ford West Bloomfield Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ahmad H. Mattour
      • Ypsilanti, Michigan, Forente stater, 48197
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
    • Minnesota
      • Bemidji, Minnesota, Forente stater, 56601
      • Coon Rapids, Minnesota, Forente stater, 55433
        • Rekruttering
        • Mercy Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Deer River, Minnesota, Forente stater, 56636
        • Rekruttering
        • Essentia Health - Deer River Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
      • Duluth, Minnesota, Forente stater, 55805
        • Rekruttering
        • Essentia Health Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
      • Edina, Minnesota, Forente stater, 55435
        • Rekruttering
        • Fairview Southdale Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Edina, Minnesota, Forente stater, 55435
        • Rekruttering
        • Minnesota Oncology - Edina
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Hibbing, Minnesota, Forente stater, 55746
        • Rekruttering
        • Essentia Health Hibbing Clinic
        • Hovedetterforsker:
          • Bret E. Friday
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 218-786-3308
      • Minneapolis, Minnesota, Forente stater, 55407
        • Rekruttering
        • Abbott-Northwestern Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Rochester, Minnesota, Forente stater, 55905
        • Rekruttering
        • Mayo Clinic in Rochester
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 855-776-0015
        • Hovedetterforsker:
          • James M. Foran
      • Saint Louis Park, Minnesota, Forente stater, 55416
        • Rekruttering
        • Park Nicollet Clinic - Saint Louis Park
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Saint Paul, Minnesota, Forente stater, 55101
        • Rekruttering
        • Regions Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Saint Paul, Minnesota, Forente stater, 55102
        • Rekruttering
        • United Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Virginia, Minnesota, Forente stater, 55792
        • Rekruttering
        • Essentia Health Virginia Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
    • Mississippi
      • Columbus, Mississippi, Forente stater, 39705
        • Rekruttering
        • Baptist Memorial Hospital and Cancer Center-Golden Triangle
        • Hovedetterforsker:
          • Salil Goorha
        • Ta kontakt med:
      • Grenada, Mississippi, Forente stater, 38901
        • Rekruttering
        • Baptist Cancer Center-Grenada
        • Hovedetterforsker:
          • Salil Goorha
        • Ta kontakt med:
      • New Albany, Mississippi, Forente stater, 38652
        • Rekruttering
        • Baptist Memorial Hospital and Cancer Center-Union County
        • Hovedetterforsker:
          • Salil Goorha
        • Ta kontakt med:
      • Oxford, Mississippi, Forente stater, 38655
        • Rekruttering
        • Baptist Memorial Hospital and Cancer Center-Oxford
        • Hovedetterforsker:
          • Salil Goorha
        • Ta kontakt med:
      • Southhaven, Mississippi, Forente stater, 38671
        • Rekruttering
        • Baptist Memorial Hospital and Cancer Center-Desoto
        • Hovedetterforsker:
          • Salil Goorha
        • Ta kontakt med:
    • Missouri
      • City of Saint Peters, Missouri, Forente stater, 63376
        • Rekruttering
        • Siteman Cancer Center at Saint Peters Hospital
        • Hovedetterforsker:
          • Geoffrey L. Uy
        • Ta kontakt med:
      • Creve Coeur, Missouri, Forente stater, 63141
        • Rekruttering
        • Siteman Cancer Center at West County Hospital
        • Hovedetterforsker:
          • Geoffrey L. Uy
        • Ta kontakt med:
      • Farmington, Missouri, Forente stater, 63640
        • Rekruttering
        • Parkland Health Center - Farmington
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Kansas City, Missouri, Forente stater, 64154
        • Rekruttering
        • University of Kansas Cancer Center - North
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tara L. Lin
      • Kansas City, Missouri, Forente stater, 64108
        • Rekruttering
        • University Health Truman Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 816-404-4375
        • Hovedetterforsker:
          • Tara L. Lin
      • Kansas City, Missouri, Forente stater, 64116
        • Rekruttering
        • University of Kansas Cancer Center - Briarcliff
        • Hovedetterforsker:
          • Tara L. Lin
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 913-588-3671
      • Lee's Summit, Missouri, Forente stater, 64064
        • Rekruttering
        • University of Kansas Cancer Center - Lee's Summit
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tara L. Lin
      • Saint Joseph, Missouri, Forente stater, 64506
        • Suspendert
        • Heartland Regional Medical Center
      • Sainte Genevieve, Missouri, Forente stater, 63670
        • Rekruttering
        • Sainte Genevieve County Memorial Hospital
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Hovedetterforsker:
          • Geoffrey L. Uy
        • Ta kontakt med:
      • St Louis, Missouri, Forente stater, 63129
        • Rekruttering
        • Siteman Cancer Center-South County
        • Hovedetterforsker:
          • Geoffrey L. Uy
        • Ta kontakt med:
      • St Louis, Missouri, Forente stater, 63136
        • Rekruttering
        • Siteman Cancer Center at Christian Hospital
        • Hovedetterforsker:
          • Geoffrey L. Uy
        • Ta kontakt med:
      • St Louis, Missouri, Forente stater, 63131
        • Rekruttering
        • Missouri Baptist Medical Center
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • St Louis, Missouri, Forente stater, 63128
        • Suspendert
        • Mercy Hospital South
      • Sullivan, Missouri, Forente stater, 63080
        • Rekruttering
        • Missouri Baptist Sullivan Hospital
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
    • Montana
      • Anaconda, Montana, Forente stater, 59711
        • Rekruttering
        • Community Hospital of Anaconda
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Billings, Montana, Forente stater, 59101
        • Rekruttering
        • Billings Clinic Cancer Center
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Bozeman, Montana, Forente stater, 59715
        • Rekruttering
        • Bozeman Health Deaconess Hospital
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Great Falls, Montana, Forente stater, 59405
        • Rekruttering
        • Benefis Sletten Cancer Institute
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Kalispell, Montana, Forente stater, 59901
        • Rekruttering
        • Logan Health Medical Center
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Missoula, Montana, Forente stater, 59802
        • Rekruttering
        • Saint Patrick Hospital - Community Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Charles W. Drescher
      • Missoula, Montana, Forente stater, 59804
        • Rekruttering
        • Community Medical Center
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
    • Nebraska
      • Bellevue, Nebraska, Forente stater, 68123
        • Rekruttering
        • Nebraska Medicine-Bellevue
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Haddadin
      • Omaha, Nebraska, Forente stater, 68198
        • Rekruttering
        • University of Nebraska Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Haddadin
      • Omaha, Nebraska, Forente stater, 68118
        • Rekruttering
        • Nebraska Medicine-Village Pointe
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 402-559-5600
        • Hovedetterforsker:
          • Michael Haddadin
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89102
        • Suspendert
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, Forente stater, 89183
        • Suspendert
        • OptumCare Cancer Care at Fort Apache
      • Reno, Nevada, Forente stater, 89502
        • Suspendert
        • Renown Regional Medical Center
    • New Hampshire
      • Lebanon, New Hampshire, Forente stater, 03756
        • Rekruttering
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Raphael A. Lizcano
    • New Jersey
      • Basking Ridge, New Jersey, Forente stater, 07920
        • Rekruttering
        • Memorial Sloan Kettering Basking Ridge
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
        • Hovedetterforsker:
          • Aaron D. Goldberg
      • Camden, New Jersey, Forente stater, 08103
        • Rekruttering
        • Cooper Hospital University Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 856-325-6757
        • Hovedetterforsker:
          • Michael Brister
      • Livingston, New Jersey, Forente stater, 07039
        • Rekruttering
        • Cooperman Barnabas Medical Center
        • Hovedetterforsker:
          • Neil D. Palmisiano
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 973-322-5200
      • Long Branch, New Jersey, Forente stater, 07740
        • Rekruttering
        • Monmouth Medical Center
        • Hovedetterforsker:
          • Neil D. Palmisiano
        • Ta kontakt med:
      • Middletown, New Jersey, Forente stater, 07748
        • Rekruttering
        • Memorial Sloan Kettering Monmouth
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
        • Hovedetterforsker:
          • Aaron D. Goldberg
      • Montvale, New Jersey, Forente stater, 07645
        • Rekruttering
        • Memorial Sloan Kettering Bergen
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
        • Hovedetterforsker:
          • Aaron D. Goldberg
      • New Brunswick, New Jersey, Forente stater, 08903
        • Rekruttering
        • Rutgers Cancer Institute of New Jersey
        • Hovedetterforsker:
          • Neil D. Palmisiano
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 732-235-7356
      • Paramus, New Jersey, Forente stater, 07652
      • Ridgewood, New Jersey, Forente stater, 07450
      • Toms River, New Jersey, Forente stater, 08755
        • Rekruttering
        • Community Medical Center
        • Hovedetterforsker:
          • Neil D. Palmisiano
        • Ta kontakt med:
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87106
        • Rekruttering
        • University of New Mexico Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Charles Foucar
    • New York
      • Buffalo, New York, Forente stater, 14263
        • Rekruttering
        • Roswell Park Cancer Institute
        • Hovedetterforsker:
          • Eunice S. Wang
        • Ta kontakt med:
      • Commack, New York, Forente stater, 11725
        • Rekruttering
        • Memorial Sloan Kettering Commack
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
        • Hovedetterforsker:
          • Aaron D. Goldberg
      • Lake Success, New York, Forente stater, 11042
        • Rekruttering
        • Northwell Health/Center for Advanced Medicine
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 516-734-8896
        • Hovedetterforsker:
          • David Chitty
      • Manhasset, New York, Forente stater, 11030
        • Rekruttering
        • North Shore University Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 516-734-8896
        • Hovedetterforsker:
          • David Chitty
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
        • Hovedetterforsker:
          • Aaron D. Goldberg
      • New York, New York, Forente stater, 10029
        • Rekruttering
        • Mount Sinai Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 212-824-7309
          • E-post: CCTO@mssm.edu
        • Hovedetterforsker:
          • Douglas A. Tremblay
      • Rochester, New York, Forente stater, 14642
        • Rekruttering
        • University of Rochester
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 585-275-5830
        • Hovedetterforsker:
          • Jane L. Liesveld
      • Rochester, New York, Forente stater, 14621
        • Rekruttering
        • Rochester General Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Maria M. Sbenghe
      • Stony Brook, New York, Forente stater, 11794
        • Rekruttering
        • Stony Brook University Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-862-2215
        • Hovedetterforsker:
          • Suhu Liu
      • Syracuse, New York, Forente stater, 13210
        • Rekruttering
        • State University of New York Upstate Medical University
        • Hovedetterforsker:
          • Teresa C. Gentile
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 315-464-5476
      • The Bronx, New York, Forente stater, 10467
        • Rekruttering
        • Montefiore Medical Center - Moses Campus
        • Hovedetterforsker:
          • Ioannis Mantzaris
        • Ta kontakt med:
      • Uniondale, New York, Forente stater, 11553
        • Rekruttering
        • Memorial Sloan Kettering Nassau
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
        • Hovedetterforsker:
          • Aaron D. Goldberg
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27599
        • Rekruttering
        • UNC Lineberger Comprehensive Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lacey S. Williams
      • Charlotte, North Carolina, Forente stater, 28203
        • Rekruttering
        • Carolinas Medical Center/Levine Cancer Institute
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-804-9376
        • Hovedetterforsker:
          • Brittany K. Ragon
      • Charlotte, North Carolina, Forente stater, 28204
        • Rekruttering
        • Novant Health Presbyterian Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Patricia L. Kropf
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University Medical Center
        • Hovedetterforsker:
          • Harry P. Erba
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 888-275-3853
      • Greenville, North Carolina, Forente stater, 27834
        • Rekruttering
        • East Carolina University
        • Hovedetterforsker:
          • Darla K. Liles
        • Ta kontakt med:
      • Wilmington, North Carolina, Forente stater, 28401
        • Rekruttering
        • Novant Health New Hanover Regional Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 910-342-3000
        • Hovedetterforsker:
          • Swaleh A. Bahamadi
      • Winston-Salem, North Carolina, Forente stater, 27157
        • Rekruttering
        • Wake Forest University Health Sciences
        • Hovedetterforsker:
          • Matthew J. Wieduwilt
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 336-713-6771
      • Winston-Salem, North Carolina, Forente stater, 27103
        • Rekruttering
        • Novant Health Forsyth Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • James P. Dugan
    • North Dakota
      • Bismarck, North Dakota, Forente stater, 58501
      • Fargo, North Dakota, Forente stater, 58122
      • Fargo, North Dakota, Forente stater, 58122
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • Rekruttering
        • Case Western Reserve University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Benjamin K. Tomlinson
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • Ohio State University Comprehensive Cancer Center
        • Hovedetterforsker:
          • Alice S. Mims
        • Ta kontakt med:
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • Rekruttering
        • University of Oklahoma Health Sciences Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Manu Pandey
    • Oregon
      • Newberg, Oregon, Forente stater, 97132
        • Rekruttering
        • Providence Newberg Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Charles W. Drescher
      • Ontario, Oregon, Forente stater, 97914
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Ontario
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Oregon City, Oregon, Forente stater, 97045
        • Rekruttering
        • Providence Willamette Falls Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Charles W. Drescher
      • Portland, Oregon, Forente stater, 97213
        • Rekruttering
        • Providence Portland Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Charles W. Drescher
      • Portland, Oregon, Forente stater, 97225
        • Rekruttering
        • Providence Saint Vincent Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Charles W. Drescher
      • Portland, Oregon, Forente stater, 97239
        • Suspendert
        • Oregon Health and Science University
    • Pennsylvania
      • Allentown, Pennsylvania, Forente stater, 18103
        • Rekruttering
        • Lehigh Valley Hospital-Cedar Crest
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tareq Al baghdadi
      • Danville, Pennsylvania, Forente stater, 17822
        • Rekruttering
        • Geisinger Medical Center
        • Hovedetterforsker:
          • Joseph J. Vadakara
        • Ta kontakt med:
      • Hershey, Pennsylvania, Forente stater, 17033-0850
        • Rekruttering
        • Penn State Milton S Hershey Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Joseph Cioccio
      • Lewistown, Pennsylvania, Forente stater, 17044
        • Rekruttering
        • Lewistown Hospital
        • Hovedetterforsker:
          • Joseph J. Vadakara
        • Ta kontakt med:
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Rekruttering
        • Thomas Jefferson University Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Margaret T. Kasner
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • University of Pennsylvania/Abramson Cancer Center
        • Hovedetterforsker:
          • Keith W. Pratz
        • Ta kontakt med:
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • Rekruttering
        • UPMC Hillman Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-647-8073
        • Hovedetterforsker:
          • Annie P. Im
      • West Reading, Pennsylvania, Forente stater, 19611
        • Rekruttering
        • Reading Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 610-988-9323
        • Hovedetterforsker:
          • Terrence P. Cescon
      • Wilkes-Barre, Pennsylvania, Forente stater, 18711
        • Rekruttering
        • Geisinger Wyoming Valley/Henry Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Joseph J. Vadakara
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02903
        • Rekruttering
        • Rhode Island Hospital
        • Hovedetterforsker:
          • John L. Reagan
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 401-444-1488
    • South Carolina
      • Boiling Springs, South Carolina, Forente stater, 29316
        • Rekruttering
        • Prisma Health Cancer Institute - Spartanburg
        • Hovedetterforsker:
          • Suzanne R. Fanning
        • Ta kontakt med:
      • Charleston, South Carolina, Forente stater, 29425
        • Rekruttering
        • Medical University of South Carolina
        • Hovedetterforsker:
          • Praneeth Baratam
        • Ta kontakt med:
      • Easley, South Carolina, Forente stater, 29640
        • Rekruttering
        • Prisma Health Cancer Institute - Easley
        • Hovedetterforsker:
          • Suzanne R. Fanning
        • Ta kontakt med:
      • Greenville, South Carolina, Forente stater, 29605
        • Rekruttering
        • Prisma Health Cancer Institute - Faris
        • Hovedetterforsker:
          • Suzanne R. Fanning
        • Ta kontakt med:
      • Greenville, South Carolina, Forente stater, 29605
        • Rekruttering
        • Prisma Health Cancer Institute - Butternut
        • Hovedetterforsker:
          • Suzanne R. Fanning
        • Ta kontakt med:
      • Greenville, South Carolina, Forente stater, 29615
        • Rekruttering
        • Prisma Health Cancer Institute - Eastside
        • Hovedetterforsker:
          • Suzanne R. Fanning
        • Ta kontakt med:
      • Greer, South Carolina, Forente stater, 29650
        • Rekruttering
        • Prisma Health Cancer Institute - Greer
        • Hovedetterforsker:
          • Suzanne R. Fanning
        • Ta kontakt med:
      • Seneca, South Carolina, Forente stater, 29672
        • Rekruttering
        • Prisma Health Cancer Institute - Seneca
        • Hovedetterforsker:
          • Suzanne R. Fanning
        • Ta kontakt med:
    • South Dakota
      • Sioux Falls, South Dakota, Forente stater, 57104
        • Rekruttering
        • Sanford Cancer Center Oncology Clinic
        • Hovedetterforsker:
          • Daniel Almquist
        • Ta kontakt med:
      • Sioux Falls, South Dakota, Forente stater, 57117-5134
    • Tennessee
      • Collierville, Tennessee, Forente stater, 38017
        • Rekruttering
        • Baptist Memorial Hospital and Cancer Center-Collierville
        • Hovedetterforsker:
          • Salil Goorha
        • Ta kontakt med:
      • Knoxville, Tennessee, Forente stater, 37920
        • Suspendert
        • University of Tennessee - Knoxville
      • Memphis, Tennessee, Forente stater, 38120
        • Rekruttering
        • Baptist Memorial Hospital and Cancer Center-Memphis
        • Hovedetterforsker:
          • Salil Goorha
        • Ta kontakt med:
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 713-798-1354
          • E-post: burton@bcm.edu
        • Hovedetterforsker:
          • Tareq Abuasab
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Ben Taub General Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 713-873-2000
        • Hovedetterforsker:
          • Tareq Abuasab
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Rekruttering
        • Huntsman Cancer Institute/University of Utah
        • Ta kontakt med:
        • Hovedetterforsker:
          • Paul J. Shami
      • Salt Lake City, Utah, Forente stater, 84148
        • Rekruttering
        • George E Wahlen Department of Veterans Affairs Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 801-582-1565
        • Hovedetterforsker:
          • Tsewang Tashi
    • Vermont
      • Burlington, Vermont, Forente stater, 05401
        • Rekruttering
        • University of Vermont Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 802-656-4101
          • E-post: rpo@uvm.edu
        • Hovedetterforsker:
          • Diego A. Adrianzen Herrera
      • Burlington, Vermont, Forente stater, 05405
        • Rekruttering
        • University of Vermont and State Agricultural College
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 802-656-8990
          • E-post: rpo@uvm.edu
        • Hovedetterforsker:
          • Diego A. Adrianzen Herrera
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • Inova Schar Cancer Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Danielle A. Shafer
      • Falls Church, Virginia, Forente stater, 22042
        • Rekruttering
        • Inova Fairfax Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Danielle A. Shafer
      • Richmond, Virginia, Forente stater, 23298
        • Rekruttering
        • VCU Massey Comprehensive Cancer Center
        • Hovedetterforsker:
          • Keri R. Maher
        • Ta kontakt med:
    • Washington
      • Edmonds, Washington, Forente stater, 98026
        • Rekruttering
        • Swedish Cancer Institute-Edmonds
        • Hovedetterforsker:
          • Charles W. Drescher
        • Ta kontakt med:
      • Issaquah, Washington, Forente stater, 98029
        • Rekruttering
        • Swedish Cancer Institute-Issaquah
        • Hovedetterforsker:
          • Charles W. Drescher
        • Ta kontakt med:
      • Seattle, Washington, Forente stater, 98122
        • Rekruttering
        • Swedish Medical Center-First Hill
        • Hovedetterforsker:
          • Charles W. Drescher
        • Ta kontakt med:
      • Seattle, Washington, Forente stater, 98195
        • Rekruttering
        • University of Washington Medical Center - Montlake
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-804-8824
        • Hovedetterforsker:
          • Jacob S. Appelbaum
      • Seattle, Washington, Forente stater, 98109
        • Rekruttering
        • Fred Hutchinson Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-804-8824
        • Hovedetterforsker:
          • Jacob S. Appelbaum
    • Wisconsin
      • Appleton, Wisconsin, Forente stater, 54911
        • Rekruttering
        • ThedaCare Regional Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yazhini Vallatharasu
      • Ashland, Wisconsin, Forente stater, 54806
        • Rekruttering
        • Duluth Clinic Ashland
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
      • Burlington, Wisconsin, Forente stater, 53105
        • Rekruttering
        • Aurora Cancer Care-Southern Lakes VLCC
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Cudahy, Wisconsin, Forente stater, 53110
        • Rekruttering
        • Aurora Saint Luke's South Shore
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Eau Claire, Wisconsin, Forente stater, 54701
      • Germantown, Wisconsin, Forente stater, 53022
        • Rekruttering
        • Aurora Health Care Germantown Health Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Grafton, Wisconsin, Forente stater, 53024
        • Rekruttering
        • Aurora Cancer Care-Grafton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Green Bay, Wisconsin, Forente stater, 54311
        • Rekruttering
        • Aurora BayCare Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Green Bay, Wisconsin, Forente stater, 54301
        • Rekruttering
        • Saint Vincent Hospital Cancer Center Green Bay
        • Hovedetterforsker:
          • Matthew L. Ryan
        • Ta kontakt med:
      • Green Bay, Wisconsin, Forente stater, 54303
        • Rekruttering
        • Saint Vincent Hospital Cancer Center at Saint Mary's
        • Hovedetterforsker:
          • Matthew L. Ryan
        • Ta kontakt med:
      • Janesville, Wisconsin, Forente stater, 53548
        • Rekruttering
        • Mercyhealth Hospital and Cancer Center - Janesville
        • Ta kontakt med:
        • Hovedetterforsker:
          • Emily G. Robinson
      • Kenosha, Wisconsin, Forente stater, 53142
        • Rekruttering
        • Aurora Cancer Care-Kenosha South
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • La Crosse, Wisconsin, Forente stater, 54601
        • Rekruttering
        • Gundersen Lutheran Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • David E. Marinier
      • Madison, Wisconsin, Forente stater, 53705
        • Rekruttering
        • William S Middleton VA Medical Center
        • Hovedetterforsker:
          • Christopher D. Fletcher
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 17007 608-256-1901
      • Madison, Wisconsin, Forente stater, 53792
        • Rekruttering
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • Hovedetterforsker:
          • Kieran D. Sahasrabudhe
        • Ta kontakt med:
      • Madison, Wisconsin, Forente stater, 53718
        • Rekruttering
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
        • Hovedetterforsker:
          • Kieran D. Sahasrabudhe
        • Ta kontakt med:
      • Marinette, Wisconsin, Forente stater, 54143
        • Rekruttering
        • Aurora Bay Area Medical Group-Marinette
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Marshfield, Wisconsin, Forente stater, 54449
      • Menomonee Falls, Wisconsin, Forente stater, 53051
        • Rekruttering
        • Froedtert Menomonee Falls Hospital
        • Hovedetterforsker:
          • Ehab L. Atallah
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 262-257-5100
      • Milwaukee, Wisconsin, Forente stater, 53209
        • Rekruttering
        • Aurora Cancer Care-Milwaukee
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Milwaukee, Wisconsin, Forente stater, 53215
        • Rekruttering
        • Aurora Saint Luke's Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Rekruttering
        • Medical College of Wisconsin
        • Hovedetterforsker:
          • Ehab L. Atallah
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 414-805-3666
      • Milwaukee, Wisconsin, Forente stater, 53233
        • Rekruttering
        • Aurora Sinai Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Minocqua, Wisconsin, Forente stater, 54548
      • Mukwonago, Wisconsin, Forente stater, 53149
        • Rekruttering
        • ProHealth D N Greenwald Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Timothy R. Wassenaar
      • New Berlin, Wisconsin, Forente stater, 53151
        • Rekruttering
        • Froedtert and MCW Moorland Reserve Health Center
        • Hovedetterforsker:
          • Ehab L. Atallah
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 414-805-0505
      • Oak Creek, Wisconsin, Forente stater, 53154
        • Rekruttering
        • Drexel Town Square Health Center
        • Hovedetterforsker:
          • Ehab L. Atallah
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 414-805-0505
      • Oconomowoc, Wisconsin, Forente stater, 53066
        • Rekruttering
        • ProHealth Oconomowoc Memorial Hospital
        • Hovedetterforsker:
          • Timothy R. Wassenaar
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 262-928-7878
      • Oconto Falls, Wisconsin, Forente stater, 54154
        • Rekruttering
        • Saint Vincent Hospital Cancer Center at Oconto Falls
        • Hovedetterforsker:
          • Matthew L. Ryan
        • Ta kontakt med:
      • Oshkosh, Wisconsin, Forente stater, 54904
        • Rekruttering
        • Vince Lombardi Cancer Clinic - Oshkosh
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Racine, Wisconsin, Forente stater, 53406
        • Rekruttering
        • Aurora Cancer Care-Racine
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Rice Lake, Wisconsin, Forente stater, 54868
      • Sheboygan, Wisconsin, Forente stater, 53081
        • Rekruttering
        • Vince Lombardi Cancer Clinic-Sheboygan
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Sheboygan, Wisconsin, Forente stater, 53081
        • Rekruttering
        • Saint Vincent Hospital Cancer Center at Sheboygan
        • Hovedetterforsker:
          • Matthew L. Ryan
        • Ta kontakt med:
      • Stevens Point, Wisconsin, Forente stater, 54482
      • Sturgeon Bay, Wisconsin, Forente stater, 54235-1495
        • Rekruttering
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
        • Hovedetterforsker:
          • Matthew L. Ryan
        • Ta kontakt med:
      • Summit, Wisconsin, Forente stater, 53066
        • Rekruttering
        • Aurora Medical Center in Summit
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Two Rivers, Wisconsin, Forente stater, 54241
        • Rekruttering
        • Vince Lombardi Cancer Clinic-Two Rivers
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Waukesha, Wisconsin, Forente stater, 53188
        • Rekruttering
        • ProHealth Waukesha Memorial Hospital
        • Hovedetterforsker:
          • Timothy R. Wassenaar
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 262-928-7632
      • Waukesha, Wisconsin, Forente stater, 53188
        • Rekruttering
        • UW Cancer Center at ProHealth Care
        • Hovedetterforsker:
          • Timothy R. Wassenaar
        • Ta kontakt med:
      • Wauwatosa, Wisconsin, Forente stater, 53226
        • Rekruttering
        • Aurora Cancer Care-Milwaukee West
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • West Allis, Wisconsin, Forente stater, 53227
        • Rekruttering
        • Aurora West Allis Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • West Bend, Wisconsin, Forente stater, 53095
        • Rekruttering
        • Froedtert West Bend Hospital/Kraemer Cancer Center
        • Hovedetterforsker:
          • Ehab L. Atallah
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 414-805-0505
      • Weston, Wisconsin, Forente stater, 54476
      • San Juan, Puerto Rico, 00927
        • Rekruttering
        • Centro Comprensivo de Cancer de UPR
        • Hovedetterforsker:
          • Luis J. Santos Reyes
        • Ta kontakt med:
      • San Juan, Puerto Rico, 00936
        • Rekruttering
        • San Juan City Hospital
        • Hovedetterforsker:
          • Luis J. Santos Reyes
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 787-763-1296

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS.

  • Participants must be >= 18 years of age.

  • Participants must not have received prior anti-cancer therapy for AML or MDS.

    • Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
    • Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m^2 of cytarabine, which is allowed for urgent cytoreduction.
  • Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of exposure.

    • Note: Participants receiving hydroxyurea prior to treatment substudy or TAP assignment must agree to discontinue hydroxyurea within 24 hours before beginning substudy or TAP treatment.
  • Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy

    • Note: active hormonal therapy is allowed
  • Participants must have a Zubrod Performance Status evaluation within 28 days prior to registration.

  • Participants must agree to have translational medicine specimens submitted.

  • Participants must be offered the opportunity to participate in specimen banking.

    • Note: Specimens must be collected and submitted following the initial paper-based process and subsequently via the Precision Medicine Specimen Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP.
  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.

    • Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
  • The master screening and reassessment protocol (MSRP) should only be used in sites where the relevant AML treatment substudies are open or if the site is willing to follow the MSRP Tier Advancement Pathway (TAP) for patients in the event that the site does not have the relevant study open and transfer to another site that does have the study open. For example, if a site does not have a myeloMATCH Tier 1 study for older AML open for enrollment, such older AML patients should only be consented for the MSRP if the site is willing to treat the patient with standard of care on TAP or is willing to transfer the patient to a center with a study open that the patient would otherwise match to.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Screening
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: MM1MDS-A01 Regimen 1 (ASTX727)

Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 2. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo bone marrow aspiration

Given PO

Andre navn:
  • ASTX727
  • CDA-hemmer E7727/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabine Tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1MDS-A01 Regimen 2 (ASTX727, enasidenib)

Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo bone marrow aspiration

Given PO

Andre navn:
  • ASTX727
  • CDA-hemmer E7727/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabine Tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given PO

Andre navn:
  • AG-221
  • CC-90007 Free Base
  • AG 221
  • AG221
Eksperimentell: MM1MDS-CTG02 Arm 1 (Luspatercept)

Patients receive luspatercept SC on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

Undergo bone marrow aspiration

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given SC

Andre navn:
  • ACE-536
  • Luspatercept-aamt
  • Reblozyl
  • ACE 536
  • ACE536
Eksperimentell: MM1MDS-CTG02 Arm 2 (Luspatercept with epoetin alfa)

Patients receive luspatercept SC on day 1 and epoetin alfa SC QW for each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

Given SC

Andre navn:
  • Epogen
  • EPO
  • Procrit
  • Eprex
  • Epoetin alfa-epbx
  • Retacrit

Undergo bone marrow aspiration

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given SC

Andre navn:
  • ACE-536
  • Luspatercept-aamt
  • Reblozyl
  • ACE 536
  • ACE536
Eksperimentell: MM1MDS-CTG02 Arm 3 (Luspatercept and emavusertib)

Patients receive luspatercept SC on day 1 and emavusertib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

Undergo bone marrow aspiration

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given SC

Andre navn:
  • ACE-536
  • Luspatercept-aamt
  • Reblozyl
  • ACE 536
  • ACE536

Given PO

Andre navn:
  • CA-4948
  • AU 4948
  • AU-4948
  • CA 4948
  • CA4948
  • Interleukin-1-reseptorassosiert Kinase 4-hemmer CA-4948
  • IRAK4-hemmer CA-4948
Eksperimentell: MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)

INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial.

Undergo biopsy

Andre navn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV or SC

Andre navn:
  • 5 AZC
  • 5-AC
  • 5-Azacytidin
  • 5-AZC
  • Azacytidin
  • Azacytidin, 5-
  • Ladakamycin
  • Mylosar
  • U-18496
  • Vidaza
  • 5-Azacitidin

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)

INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial.

Undergo biopsy

Andre navn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV or SC

Andre navn:
  • 5 AZC
  • 5-AC
  • 5-Azacytidin
  • 5-AZC
  • Azacytidin
  • Azacytidin, 5-
  • Ladakamycin
  • Mylosar
  • U-18496
  • Vidaza
  • 5-Azacitidin

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given PO

Andre navn:
  • ASP2215
  • ASP-2215
  • ASP 2215
Eksperimentell: MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)

INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial.

Undergo biopsy

Andre navn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV or SC

Andre navn:
  • 5 AZC
  • 5-AC
  • 5-Azacytidin
  • 5-AZC
  • Azacytidin
  • Azacytidin, 5-
  • Ladakamycin
  • Mylosar
  • U-18496
  • Vidaza
  • 5-Azacitidin

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given PO

Andre navn:
  • ASP2215
  • ASP-2215
  • ASP 2215
Aktiv komparator: MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax)

Patients receive ASTX727 PO QD on days 1-5 of each cycle and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo bone marrow aspiration

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given PO

Andre navn:
  • ASTX727
  • CDA-hemmer E7727/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabine Tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)

Patients receive ASTX727 PO QD on days 1-5 of each cycle, venetoclax PO QD on days 1-28 of each cycle, and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo bone marrow aspiration

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given PO

Andre navn:
  • ASTX727
  • CDA-hemmer E7727/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabine Tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given PO

Andre navn:
  • FT 2102
  • FT-2102
  • FT2102
  • IDH1-R132 Inhibitor FT-2102
  • Rezlidhia
Eksperimentell: MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib)

Patients receive ASTX727 PO QD on days 1-5 of each cycle and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo bone marrow aspiration

Given PO

Andre navn:
  • ASTX727
  • CDA-hemmer E7727/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabine Tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given PO

Andre navn:
  • FT 2102
  • FT-2102
  • FT2102
  • IDH1-R132 Inhibitor FT-2102
  • Rezlidhia
Aktiv komparator: MM1OA-MDS-A05 Cohort B, Arm 4 (ASTX727)

Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients without CR after cycle 6 may then cross-over to Arm 3. Patients with CR, as well as patients without CR but deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo bone marrow aspiration

Given PO

Andre navn:
  • ASTX727
  • CDA-hemmer E7727/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabine Tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1OA-MDS-A05 Cohort C (olutasidenib)

Patients receive olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo bone marrow aspiration

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given PO

Andre navn:
  • FT 2102
  • FT-2102
  • FT2102
  • IDH1-R132 Inhibitor FT-2102
  • Rezlidhia
Aktiv komparator: MM1OA-S03 Arm 1 (ASTX727, venetoclax)

Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo bone marrow aspiration

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given PO

Andre navn:
  • ASTX727
  • CDA-hemmer E7727/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabine Tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)

Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo bone marrow aspiration

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given PO

Andre navn:
  • ASTX727
  • CDA-hemmer E7727/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabine Tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given PO

Andre navn:
  • AG-221
  • CC-90007 Free Base
  • AG 221
  • AG221
Aktiv komparator: MM1OA-S04 Arm 1 (ASTX727 with standard duration venetoclax)

Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

Undergo bone marrow aspiration

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given PO

Andre navn:
  • ASTX727
  • CDA-hemmer E7727/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabine Tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1OA-S04 Arm 2 (ASTX727 with shorter duration venetoclax)

Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

Undergo bone marrow aspiration

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given PO

Andre navn:
  • ASTX727
  • CDA-hemmer E7727/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabin kombinasjonsmiddel ASTX727
  • Cedazuridin/Decitabine Tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Aktiv komparator: MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)

Patients receive gemtuzumab ozogamicin IV on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study.

Given IV

Andre navn:
  • P-Cytosin-arabinosid
  • 1-P-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-B-D-Arabinofuranosylcytosin
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-Beta-D-arabinofuranosylcytosin
  • 1P-D-Arabinofuranosylcytosin
  • 2(1H)-pyrimidinon, 4-amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-pyrimidinon, 4-amino-lß-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-celle
  • Arabine
  • Arabinofuranosylcytosin
  • Arabinosylcytosin
  • Aracytidin
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosin Arabinoside
  • Cytosin-p-arabinosid
  • Cytosin-beta-arabinosid
  • Erpalfa
  • Starasid
  • Tarabin PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Given IV

Andre navn:
  • Mylotarg
  • Calicheamicin-konjugert humanisert anti-CD33 monoklonalt antistoff
  • CDP-771
  • CMA-676
  • gemtuzumab
  • hP67.6-Calicheamicin
  • WAY-CMA-676

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given IV

Andre navn:
  • Cerubidin
  • Cloridrato de Daunorubicina
  • Daunoblastin
  • Daunoblastina
  • Daunomycin hydroklorid
  • Daunomycin, hydroklorid
  • Daunorubicin.HCl
  • Daunorubicini Hydrochloridum
  • FI-6339
  • Ondena
  • RP-13057
  • Rubidomycin hydroklorid
  • Rubilem

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Receive SOC treatment

Andre navn:
  • velferdstandard
  • standard terapi
Eksperimentell: MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)

Patients receive venetoclax PO QD on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study.

Given IV

Andre navn:
  • P-Cytosin-arabinosid
  • 1-P-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-B-D-Arabinofuranosylcytosin
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-Beta-D-arabinofuranosylcytosin
  • 1P-D-Arabinofuranosylcytosin
  • 2(1H)-pyrimidinon, 4-amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-pyrimidinon, 4-amino-lß-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-celle
  • Arabine
  • Arabinofuranosylcytosin
  • Arabinosylcytosin
  • Aracytidin
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosin Arabinoside
  • Cytosin-p-arabinosid
  • Cytosin-beta-arabinosid
  • Erpalfa
  • Starasid
  • Tarabin PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given IV

Andre navn:
  • Cerubidin
  • Cloridrato de Daunorubicina
  • Daunoblastin
  • Daunoblastina
  • Daunomycin hydroklorid
  • Daunomycin, hydroklorid
  • Daunorubicin.HCl
  • Daunorubicini Hydrochloridum
  • FI-6339
  • Ondena
  • RP-13057
  • Rubidomycin hydroklorid
  • Rubilem

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Receive SOC treatment

Andre navn:
  • velferdstandard
  • standard terapi
Eksperimentell: MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)

Patients receive daunorubicin IV on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax PO QD on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

Given IV

Andre navn:
  • P-Cytosin-arabinosid
  • 1-P-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-B-D-Arabinofuranosylcytosin
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-Beta-D-arabinofuranosylcytosin
  • 1P-D-Arabinofuranosylcytosin
  • 2(1H)-pyrimidinon, 4-amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-pyrimidinon, 4-amino-lß-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-celle
  • Arabine
  • Arabinofuranosylcytosin
  • Arabinosylcytosin
  • Aracytidin
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosin Arabinoside
  • Cytosin-p-arabinosid
  • Cytosin-beta-arabinosid
  • Erpalfa
  • Starasid
  • Tarabin PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given IV

Andre navn:
  • Cerubidin
  • Cloridrato de Daunorubicina
  • Daunoblastin
  • Daunoblastina
  • Daunomycin hydroklorid
  • Daunomycin, hydroklorid
  • Daunorubicin.HCl
  • Daunorubicini Hydrochloridum
  • FI-6339
  • Ondena
  • RP-13057
  • Rubidomycin hydroklorid
  • Rubilem

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1YA-CTG01 Arm II (azacitidine, venetoclax)

Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV or SC

Andre navn:
  • 5 AZC
  • 5-AC
  • 5-Azacytidin
  • 5-AZC
  • Azacytidin
  • Azacytidin, 5-
  • Ladakamycin
  • Mylosar
  • U-18496
  • Vidaza
  • 5-Azacitidin

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Aktiv komparator: MM1YA-CTG01 Arm III (daunorubicin, cytarabine)

Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

Given IV

Andre navn:
  • P-Cytosin-arabinosid
  • 1-P-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-B-D-Arabinofuranosylcytosin
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-Beta-D-arabinofuranosylcytosin
  • 1P-D-Arabinofuranosylcytosin
  • 2(1H)-pyrimidinon, 4-amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-pyrimidinon, 4-amino-lß-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-celle
  • Arabine
  • Arabinofuranosylcytosin
  • Arabinosylcytosin
  • Aracytidin
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosin Arabinoside
  • Cytosin-p-arabinosid
  • Cytosin-beta-arabinosid
  • Erpalfa
  • Starasid
  • Tarabin PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given IV

Andre navn:
  • Cerubidin
  • Cloridrato de Daunorubicina
  • Daunoblastin
  • Daunoblastina
  • Daunomycin hydroklorid
  • Daunomycin, hydroklorid
  • Daunorubicin.HCl
  • Daunorubicini Hydrochloridum
  • FI-6339
  • Ondena
  • RP-13057
  • Rubidomycin hydroklorid
  • Rubilem

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)

See Detailed Description.

Given IV

Andre navn:
  • P-Cytosin-arabinosid
  • 1-P-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-B-D-Arabinofuranosylcytosin
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-Beta-D-arabinofuranosylcytosin
  • 1P-D-Arabinofuranosylcytosin
  • 2(1H)-pyrimidinon, 4-amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-pyrimidinon, 4-amino-lß-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-celle
  • Arabine
  • Arabinofuranosylcytosin
  • Arabinosylcytosin
  • Aracytidin
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosin Arabinoside
  • Cytosin-p-arabinosid
  • Cytosin-beta-arabinosid
  • Erpalfa
  • Starasid
  • Tarabin PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given IV

Andre navn:
  • DNR
  • Rubidomycin
  • Daunomycin
  • Daunorrubicina
  • Leukaemomycin C
  • Rubomycin C

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given PO

Andre navn:
  • AC-220
  • AC010220
  • AC220
  • ASP2689
  • Vanflyta
  • AC 220
  • ASP 2689
  • ASP-2689
Eksperimentell: MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)

See Detailed Description.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV or SC

Andre navn:
  • 5 AZC
  • 5-AC
  • 5-Azacytidin
  • 5-AZC
  • Azacytidin
  • Azacytidin, 5-
  • Ladakamycin
  • Mylosar
  • U-18496
  • Vidaza
  • 5-Azacitidin

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given PO

Andre navn:
  • AC-220
  • AC010220
  • AC220
  • ASP2689
  • Vanflyta
  • AC 220
  • ASP 2689
  • ASP-2689
Aktiv komparator: MM1YA-S01 Arm I (cytarabine, daunorubicin)

Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

Given IV

Andre navn:
  • P-Cytosin-arabinosid
  • 1-P-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-B-D-Arabinofuranosylcytosin
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-Beta-D-arabinofuranosylcytosin
  • 1P-D-Arabinofuranosylcytosin
  • 2(1H)-pyrimidinon, 4-amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-pyrimidinon, 4-amino-lß-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-celle
  • Arabine
  • Arabinofuranosylcytosin
  • Arabinosylcytosin
  • Aracytidin
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosin Arabinoside
  • Cytosin-p-arabinosid
  • Cytosin-beta-arabinosid
  • Erpalfa
  • Starasid
  • Tarabin PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given IV

Andre navn:
  • Cerubidin
  • Cloridrato de Daunorubicina
  • Daunoblastin
  • Daunoblastina
  • Daunomycin hydroklorid
  • Daunomycin, hydroklorid
  • Daunorubicin.HCl
  • Daunorubicini Hydrochloridum
  • FI-6339
  • Ondena
  • RP-13057
  • Rubidomycin hydroklorid
  • Rubilem

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)

Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

Given IV

Andre navn:
  • P-Cytosin-arabinosid
  • 1-P-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-B-D-Arabinofuranosylcytosin
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-Beta-D-arabinofuranosylcytosin
  • 1P-D-Arabinofuranosylcytosin
  • 2(1H)-pyrimidinon, 4-amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-pyrimidinon, 4-amino-lß-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-celle
  • Arabine
  • Arabinofuranosylcytosin
  • Arabinosylcytosin
  • Aracytidin
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosin Arabinoside
  • Cytosin-p-arabinosid
  • Cytosin-beta-arabinosid
  • Erpalfa
  • Starasid
  • Tarabin PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given IV

Andre navn:
  • Cerubidin
  • Cloridrato de Daunorubicina
  • Daunoblastin
  • Daunoblastina
  • Daunomycin hydroklorid
  • Daunomycin, hydroklorid
  • Daunorubicin.HCl
  • Daunorubicini Hydrochloridum
  • FI-6339
  • Ondena
  • RP-13057
  • Rubidomycin hydroklorid
  • Rubilem

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1YA-S01 Arm III (azacitidine, venetoclax)

Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV or SC

Andre navn:
  • 5 AZC
  • 5-AC
  • 5-Azacytidin
  • 5-AZC
  • Azacytidin
  • Azacytidin, 5-
  • Ladakamycin
  • Mylosar
  • U-18496
  • Vidaza
  • 5-Azacitidin

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1YA-S01 Arm IV (Vyxeos)

Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given IV

Andre navn:
  • CPX-351
  • Cytarabin-Daunorubicin liposom for injeksjon
  • Daunorubicin og Cytarabin (Liposomal)
  • Liposomal AraC-Daunorubicin CPX-351
  • Liposomal Cytarabin-Daunorubicin
  • Liposom-innkapslet kombinasjon av Daunorubicin og Cytarabin
  • Vyxeos
  • Cytarabin og Daunorubicin Liposomal
  • CPX 351
  • CPX351

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: MM1YA-S01 Arm V (Vyxeos, venetoclax)

Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo bone marrow aspiration

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV

Andre navn:
  • CPX-351
  • Cytarabin-Daunorubicin liposom for injeksjon
  • Daunorubicin og Cytarabin (Liposomal)
  • Liposomal AraC-Daunorubicin CPX-351
  • Liposomal Cytarabin-Daunorubicin
  • Liposom-innkapslet kombinasjon av Daunorubicin og Cytarabin
  • Vyxeos
  • Cytarabin og Daunorubicin Liposomal
  • CPX 351
  • CPX351

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Aktiv komparator: MM2YA-EA01 Arm A (cytarabine)

Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.

Given IV

Andre navn:
  • P-Cytosin-arabinosid
  • 1-P-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-B-D-Arabinofuranosylcytosin
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-Beta-D-arabinofuranosylcytosin
  • 1P-D-Arabinofuranosylcytosin
  • 2(1H)-pyrimidinon, 4-amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-pyrimidinon, 4-amino-lß-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-celle
  • Arabine
  • Arabinofuranosylcytosin
  • Arabinosylcytosin
  • Aracytidin
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosin Arabinoside
  • Cytosin-p-arabinosid
  • Cytosin-beta-arabinosid
  • Erpalfa
  • Starasid
  • Tarabin PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo biopsy

Andre navn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi
Eksperimentell: MM2YA-EA01 Arm B (cytarabine, venetoclax)

Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.

Given IV

Andre navn:
  • P-Cytosin-arabinosid
  • 1-P-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-B-D-Arabinofuranosylcytosin
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinon
  • 1-Beta-D-arabinofuranosylcytosin
  • 1P-D-Arabinofuranosylcytosin
  • 2(1H)-pyrimidinon, 4-amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-pyrimidinon, 4-amino-lß-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-celle
  • Arabine
  • Arabinofuranosylcytosin
  • Arabinosylcytosin
  • Aracytidin
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosin Arabinoside
  • Cytosin-p-arabinosid
  • Cytosin-beta-arabinosid
  • Erpalfa
  • Starasid
  • Tarabin PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo biopsy

Andre navn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199
Eksperimentell: MM2YA-EA01 Arm C (Vyxeos, venetoclax)

Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo biopsy

Andre navn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV

Andre navn:
  • CPX-351
  • Cytarabin-Daunorubicin liposom for injeksjon
  • Daunorubicin og Cytarabin (Liposomal)
  • Liposomal AraC-Daunorubicin CPX-351
  • Liposomal Cytarabin-Daunorubicin
  • Liposom-innkapslet kombinasjon av Daunorubicin og Cytarabin
  • Vyxeos
  • Cytarabin og Daunorubicin Liposomal
  • CPX 351
  • CPX351
Eksperimentell: MM2YA-EA01 Arm D (azacitidine, venetoclax)

Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo biopsy

Andre navn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV or SC

Andre navn:
  • 5 AZC
  • 5-AC
  • 5-Azacytidin
  • 5-AZC
  • Azacytidin
  • Azacytidin, 5-
  • Ladakamycin
  • Mylosar
  • U-18496
  • Vidaza
  • 5-Azacitidin
Eksperimentell: MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)

Patients receive venetoclax PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo PET

Andre navn:
  • Medisinsk bildebehandling, positronemisjonstomografi
  • KJÆLEDYR
  • PET-skanning
  • Positron Emission Tomography Scan
  • Positron-utslippstomografi
  • PT
  • Positronemisjonstomografi (prosedyre)

Given IV

Andre navn:
  • Busulfex
  • Misulfan
  • Mitosan
  • Myeloleukon
  • Myelosan
  • 1,4-bis[metansulfonoksy]butan
  • BUSS
  • Bussulfam
  • Busulfanum
  • Busulfan
  • CB 2041
  • CB-2041
  • Glyzophrol
  • GT 41
  • GT-41
  • Joacamine
  • Metansulfonsyre tetrametylenester
  • Metansulfonsyre, tetrametylenester
  • Mielucin
  • Misulban
  • Myeleukon
  • Mylecytan
  • Myleran
  • Sulfabutin
  • Tetrametylenbis(metansulfonat)
  • Tetrametylen bis[metansulfonat]
  • WR-19508
  • Busilvex

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV

Andre navn:
  • Fluradosa

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given IV

Andre navn:
  • Allogen
  • Allogen hematopoetisk celletransplantasjon
  • Allogen stamcelletransplantasjon
  • HSC
  • HSCT
  • Stamcelletransplantasjon, allogen

Undergo chest x-ray

Andre navn:
  • Røntgen av brystet

Given IV

Andre navn:
  • CB-3025
  • L-PAM
  • L-Sarcolysin
  • Alanin nitrogen sennep
  • L-fenylalanin sennep
  • L-Sarcolysin Fenylalanin sennep
  • L-sarkolysin
  • Melphalanum
  • Fenylalanin sennep
  • Fenylalanin nitrogen sennep
  • Sarkoklorin
  • Sarkolysin
  • WR-19813
  • Melphalan for injeksjon-leverleveringssystem
Placebo komparator: MM3TCT-A03 Conditioning 1B (matched donors with placebo)

Patients receive placebo PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo PET

Andre navn:
  • Medisinsk bildebehandling, positronemisjonstomografi
  • KJÆLEDYR
  • PET-skanning
  • Positron Emission Tomography Scan
  • Positron-utslippstomografi
  • PT
  • Positronemisjonstomografi (prosedyre)

Given IV

Andre navn:
  • Busulfex
  • Misulfan
  • Mitosan
  • Myeloleukon
  • Myelosan
  • 1,4-bis[metansulfonoksy]butan
  • BUSS
  • Bussulfam
  • Busulfanum
  • Busulfan
  • CB 2041
  • CB-2041
  • Glyzophrol
  • GT 41
  • GT-41
  • Joacamine
  • Metansulfonsyre tetrametylenester
  • Metansulfonsyre, tetrametylenester
  • Mielucin
  • Misulban
  • Myeleukon
  • Mylecytan
  • Myleran
  • Sulfabutin
  • Tetrametylenbis(metansulfonat)
  • Tetrametylen bis[metansulfonat]
  • WR-19508
  • Busilvex

Given IV

Andre navn:
  • Fluradosa

Given PO

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given IV

Andre navn:
  • Allogen
  • Allogen hematopoetisk celletransplantasjon
  • Allogen stamcelletransplantasjon
  • HSC
  • HSCT
  • Stamcelletransplantasjon, allogen

Undergo chest x-ray

Andre navn:
  • Røntgen av brystet

Given IV

Andre navn:
  • CB-3025
  • L-PAM
  • L-Sarcolysin
  • Alanin nitrogen sennep
  • L-fenylalanin sennep
  • L-Sarcolysin Fenylalanin sennep
  • L-sarkolysin
  • Melphalanum
  • Fenylalanin sennep
  • Fenylalanin nitrogen sennep
  • Sarkoklorin
  • Sarkolysin
  • WR-19813
  • Melphalan for injeksjon-leverleveringssystem
Eksperimentell: MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)

Patients receive venetoclax PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo PET

Andre navn:
  • Medisinsk bildebehandling, positronemisjonstomografi
  • KJÆLEDYR
  • PET-skanning
  • Positron Emission Tomography Scan
  • Positron-utslippstomografi
  • PT
  • Positronemisjonstomografi (prosedyre)

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Given IV

Andre navn:
  • Fluradosa

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given IV

Andre navn:
  • Allogen
  • Allogen hematopoetisk celletransplantasjon
  • Allogen stamcelletransplantasjon
  • HSC
  • HSCT
  • Stamcelletransplantasjon, allogen

Undergo chest x-ray

Andre navn:
  • Røntgen av brystet

Given IV

Andre navn:
  • CB-3025
  • L-PAM
  • L-Sarcolysin
  • Alanin nitrogen sennep
  • L-fenylalanin sennep
  • L-Sarcolysin Fenylalanin sennep
  • L-sarkolysin
  • Melphalanum
  • Fenylalanin sennep
  • Fenylalanin nitrogen sennep
  • Sarkoklorin
  • Sarkolysin
  • WR-19813
  • Melphalan for injeksjon-leverleveringssystem

Undergo total body irradiation

Andre navn:
  • Total kroppsbestråling
  • TBI
  • SCT_TBI
  • Helkroppsbestråling
  • Hele kroppen
Placebo komparator: MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)

Patients receive placebo PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC

Undergo PET

Andre navn:
  • Medisinsk bildebehandling, positronemisjonstomografi
  • KJÆLEDYR
  • PET-skanning
  • Positron Emission Tomography Scan
  • Positron-utslippstomografi
  • PT
  • Positronemisjonstomografi (prosedyre)

Given IV

Andre navn:
  • Fluradosa

Given PO

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given IV

Andre navn:
  • Allogen
  • Allogen hematopoetisk celletransplantasjon
  • Allogen stamcelletransplantasjon
  • HSC
  • HSCT
  • Stamcelletransplantasjon, allogen

Undergo chest x-ray

Andre navn:
  • Røntgen av brystet

Given IV

Andre navn:
  • CB-3025
  • L-PAM
  • L-Sarcolysin
  • Alanin nitrogen sennep
  • L-fenylalanin sennep
  • L-Sarcolysin Fenylalanin sennep
  • L-sarkolysin
  • Melphalanum
  • Fenylalanin sennep
  • Fenylalanin nitrogen sennep
  • Sarkoklorin
  • Sarkolysin
  • WR-19813
  • Melphalan for injeksjon-leverleveringssystem

Undergo total body irradiation

Andre navn:
  • Total kroppsbestråling
  • TBI
  • SCT_TBI
  • Helkroppsbestråling
  • Hele kroppen
Eksperimentell: MM3TCT-A03 Maintenance I (venetoclax)

Patients receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid ventrikulogramskanning
  • Gated Heart Pool Scan
  • RNV Scan

Undergo PET

Andre navn:
  • Medisinsk bildebehandling, positronemisjonstomografi
  • KJÆLEDYR
  • PET-skanning
  • Positron Emission Tomography Scan
  • Positron-utslippstomografi
  • PT
  • Positronemisjonstomografi (prosedyre)

Given PO

Andre navn:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto
  • ABT 199
  • GDC 0199
  • GDC0199

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Placebo komparator: MM3TCT-A03 Maintenance II (placebo)

Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study.

Undergo bone marrow biopsy

Andre navn:
  • Biopsi av benmarg
  • Biopsi, benmarg

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo PET

Andre navn:
  • Medisinsk bildebehandling, positronemisjonstomografi
  • KJÆLEDYR
  • PET-skanning
  • Positron Emission Tomography Scan
  • Positron-utslippstomografi
  • PT
  • Positronemisjonstomografi (prosedyre)

Given PO

Undergo collection of blood, urine, and/or buccal swab samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Eksperimentell: Screening (mutation carrier screening)

Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a specific substudy containing a therapy targeted to the patient's mutational profile. If there is no targetable mutation, the patient is placed on a substudy testing novel combinations that do not contain a target-specific drug. Patients who are not eligible for any MYELOMATCH substudy are assigned to TAP.

Undergo rapid genetic testing

Eksperimentell: TAP (SOC treatment, mutation carrier screening)

Patients continue SOC treatment and undergo continued bone marrow aspiration and blood collection for possible future substudy assignment.

Receive SOC treatment

Andre navn:
  • velferdstandard
  • standard terapi

Undergo rapid genetic testing

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment
Tidsramme: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Will evaluate the feasibility of MATCHBox generating all data needed for assignment to a myeloMATCH clinical trial or determination that no assignment is available, within 72 hours of MDNet receipt of specimens for initial therapy and within 10 days for subsequent therapy. For first treatment assignment and separately for each subsequent treatment assignments: every 50 participants for the first 250 participants and then every 100 participants thereafter, the proportion of participants (cumulative and new participants since prior analysis) with all MDNet data needed to determine a treatment assignment within 72 hours for first assignment and 10 days for subsequent assignments after the MDNet receives specimens will be tallied.

Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time to MDNet generating all data required for treatment substudy or TAP assignment
Tidsramme: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening).

Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
Time to treatment substudy or TAP assignment
Tidsramme: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening).

Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
Percent assigned to a myeloMATCH clinical trial
Tidsramme: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening).

Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
Percent of screened participants who register to a treatment substudy
Tidsramme: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening).

Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
Assignment to higher tier treatment substudies within myeloMATCH
Tidsramme: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening).

Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
Adverse events
Tidsramme: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening).

Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
Minimal residual disease (MRD) response
Tidsramme: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

MRD response is based on flow cytometry studies performed by the MDnet.

Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
Time-to-event outcomes for exploratory analysis
Tidsramme: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening).

Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
Performance status
Tidsramme: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Participants will be graded according to the Zubrod performance status scale.

Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Jerald P Radich, SWOG Cancer Research Network

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

18. juni 2024

Primær fullføring (Antatt)

15. mai 2029

Studiet fullført (Antatt)

15. mai 2029

Datoer for studieregistrering

Først innsendt

27. september 2022

Først innsendt som oppfylte QC-kriteriene

29. september 2022

Først lagt ut (Faktiske)

3. oktober 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. oktober 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • NCI-2022-07006
  • U10CA180888 (U.S. NIH-stipend/kontrakt)
  • NCI-2022-07006 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
  • MYELOMATCH (Annen identifikator: CTEP)
  • MYELOMATCH (Annen identifikator: SWOG)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere